Ranbaxy Laboratories is trading higher by 1.5% to Rs 423, extending its over 9% rally in past six trading sessions, in an otherwise weak market on the Bombay Stock Exchange (BSE).
The stock has outperformed the market by surging 11% in past seven trading sessions after the pharmaceutical company as entered into an in-licensing agreement with Alembic Pharmaceuticals to exclusively market the generic version of Pfizer Inc’s anti-depression drug Pristiq in the US. The BSE benchmark Sensex and the pharma sector have gain 3% each during the same period.
Meanwhile, an analyst at Edelweiss Securities has upgraded the stock to “buy” with target price of Rs 490 per share.
“The management expects growth momentum to continue led by higher contribution from US on back of launches such as Absorica, Desvenlafaxine and Lipitor,” analyst said in a recent report.
Nomura has also upgraded the stock to "buy" from "neutral" and raised its target price to Rs 475 rupees from Rs 415.
"The organisational restructuring has brought greater clarity and there is strong commitment towards improvement in margins, in our assessment," Nomura said in a note, the Reuters report suggests.
The stock has outperformed the market by surging 11% in past seven trading sessions after the pharmaceutical company as entered into an in-licensing agreement with Alembic Pharmaceuticals to exclusively market the generic version of Pfizer Inc’s anti-depression drug Pristiq in the US. The BSE benchmark Sensex and the pharma sector have gain 3% each during the same period.
Meanwhile, an analyst at Edelweiss Securities has upgraded the stock to “buy” with target price of Rs 490 per share.
“The management expects growth momentum to continue led by higher contribution from US on back of launches such as Absorica, Desvenlafaxine and Lipitor,” analyst said in a recent report.
Nomura has also upgraded the stock to "buy" from "neutral" and raised its target price to Rs 475 rupees from Rs 415.
"The organisational restructuring has brought greater clarity and there is strong commitment towards improvement in margins, in our assessment," Nomura said in a note, the Reuters report suggests.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%